Teng Junjie, Zhou Kai, Lv Dongxiao, Wu Changshun, Feng Hong
Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Department of Radiotherapy, The Third Affiliated Hospital of Shandong First Medical University, Jinan, China.
Front Pharmacol. 2022 May 23;13:714408. doi: 10.3389/fphar.2022.714408. eCollection 2022.
Lung cancer is the most common solid tumor in the worldwide. Targeted therapy and immunotherapy are important treatment options in advanced non-small cell lung cancer (NSCLC). The association of PTEN mutation and tumor immunotherapy is less established for patients with NSCLC. We present the case of an Asian woman diagnosed with stage IV lung adenocarcinoma harboring an ERBB2 mutation. She received Nivolumab treatment when her disease progresses after previous chemotherapy and Afatinib treatment. However, the patient did not response to Nivolumab. PTEN mutation was detected by next-generation sequencing (NGS) after treatment with Nivolumab. PTEN, a secondary mutation, may be served as a biomarker of resistance to anti-PD-1 immunotherapy in lung adenocarcinoma. The relationship between PTEN mutation and immunotherapy is complex and needs further study.
肺癌是全球最常见的实体瘤。靶向治疗和免疫治疗是晚期非小细胞肺癌（NSCLC）的重要治疗选择。对于NSCLC患者，PTEN突变与肿瘤免疫治疗之间的关联尚不明确。我们报告了一例亚洲女性病例，该患者被诊断为IV期肺腺癌，携带ERBB2突变。在先前的化疗和阿法替尼治疗后疾病进展时，她接受了纳武利尤单抗治疗。然而，该患者对纳武利尤单抗无反应。在接受纳武利尤单抗治疗后，通过二代测序（NGS）检测到PTEN突变。PTEN作为一种继发突变，可能是肺腺癌抗PD-1免疫治疗耐药的生物标志物。PTEN突变与免疫治疗之间的关系复杂，需要进一步研究。
